HCAb Antibodies: The Simplest Path to Bispecifics

Fully-human heavy-chain-only antibodies (HCAbs) are reshaping how developers approach bispecific and multispecific antibody manufacturing. For teams navigating the structural and immunogenicity trade-offs of compact binder formats, understanding how fully-human HCAbs differ from scFvs, VHHs, and conventional IgGs is essential before committing to a discovery platform.

What is a fully-human heavy-chain-only antibody (HCAb)?

A heavy-chain-only antibody (HCAb) is an antibody format composed entirely of two heavy chains, with no light chains, and no CH1 domain. The antigen-binding unit is a single variable heavy domain, approximately 12-15 kDa, compared to the ~150 kDa of a conventional two-heavy, two-light chain (H2L2) IgG. The full HCAb in IgG format weighs approximately 90 kDa, retaining an Fc region for half-life and effector function while eliminating the structural complexity introduced by light chain pairing.

This architecture was first observed in camelid species in 1989. Nona Biosciences produces fully human HCAbs through Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies), a platform developed from foundational work by Dr. Frank Grosveld at Erasmus MC in 2006, with fully human HCAb generation achieved by 2016.

Is an HCAb VH the same as a VHH nanobody?

Harbour Mice® HCAb VH single domains and VHH nanobodies are structurally related but scientifically and clinically distinct. Both are derived from heavy-chain-only formats, and both constitute a single-domain antigen-binding unit, but VHHs are derived from camelid species and carry non-human sequence frameworks that require humanization before clinical use.

Humanization introduces residual non-human residues and engineering trade-offs that can affect stability, affinity, and immunogenicity. Fully human VH domains from HCAb Harbour Mice® are produced through natural immune selection in a transgenic mouse system encoding human VH gene segments, meaning the resulting sequences are 100% human in origin, not engineered approximations of human sequence. This distinction matters directly for IND-enabling studies, where immunogenicity risk assessment is a regulatory consideration.

What is the difference between fully human and humanized antibodies?

Fully human antibodies carry 100% human sequence, generated in vivo through natural immune selection, as occurs in Harbour Mice®. Humanized antibodies are non-human sequences, typically murine or camelid, that have been engineered to replace non-human framework residues with human equivalents to reduce immunogenicity.

The critical difference in fully human vs humanized monoclonal antibody development is that humanized antibodies retain residual non-human residues, which carry an inherent immunogenicity risk that cannot be fully eliminated through engineering. Fully human sequences are inherently compatible with human immune tolerance because they were never non-human to begin with. For developers targeting IND filing, this distinction affects both the regulatory immunogenicity package and the long-term clinical risk profile of the molecule.

Why do HCAbs simplify bispecific and multispecific antibody manufacturing?

Chain mispairing is the central manufacturing problem in conventional bispecific antibody production. Standard H2L2 IgG bispecifics require two different heavy chains and two different light chains to assemble correctly, but during expression, heavy and light chains from different arms can pair with each other randomly, generating mismatched, non-functional species that must be separated downstream.

HCAbs eliminate this problem entirely. Because HCAb VH domains contain no light chain, there is no light chain available to mispair. Each VH domain folds and binds independently, and multispecific constructs built from HCAb-derived VH binders can be assembled without the combinatorial mispairing risk that plagues conventional bispecific formats. This structural simplicity translates directly into cleaner expression profiles, simpler purification, and more predictable manufacturing at scale.

Do HCAb VH domains have known developability challenges, and how does Nona address them?

A common question from discovery scientists concerns the VH/VL interface in conventional antibodies: when light chains are removed, the framework 2 region of a VH domain can expose hydrophobic patches that were previously buried by the light chain. In standard VH domains, this exposure can promote aggregation and compromise solubility.

Nona’s HCAb Harbour Mice® address this structurally. The VH domains generated through Harbour Mice® are produced in an in vivo context where no light chain is present during immune selection — meaning the immune system itself selects for VH sequences that fold stably as standalone domains without the light chain scaffold.

This natural selection process favors sequences, such as those from the HCAb V3 gene family, that have evolved to maintain solubility and low aggregation propensity as single domains. Nona Biologics’ Hu-mAtrIx® AI-platform integrated in discovery extends this further by guiding the incorporation of additional developability engineering to produce VH binders optimized for the biophysical demands of clinical development, including thermal stability, low viscosity, and aggregation resistance.

Nona’s integrated developability assessment pipeline evaluates these properties systematically early in the discovery process, enabling triage of candidates before costly late-stage attrition.

How does Nona’s HBICE® platform use HCAbs for T cell engagers?

HBICE® (Nona’s multispecific immune cell engager platform built on HCAb-derived binders) leverages fully human VH domains from Harbour Mice® to build structurally versatile T cell engager (TCE) constructs. TCEs are multispecific antibodies that bridge a T cell surface molecule, typically CD3, with a tumor-associated antigen to form an immune synapse and trigger cytotoxic killing.

Conventional TCE formats built on scFv binders require linker engineering and face stability challenges that can compromise the therapeutic window. HBICE® uses affinity-tuned CD3 binders to balance cytotoxicity against cytokine release, a critical optimization parameter for maximizing therapeutic index. In a published CD19/CD3 TCE case study, Nona’s CAR-based functional screening platform identified 131 unique CD19-specific VH sequences from a single immunization campaign, corresponding to a 60% positivity rate, with 55 unique sequences advancing to TCE screening after binding characterization by ELISA, flow cytometry, and Octet.

What affinity and developability benchmarks do HCAbs from Harbour Mice® achieve?

HCAbs generated through Harbour Mice® routinely achieve sub-nanomolar to low nanomolar binding affinities. Developability metrics are evaluated systematically: Nona’s integrated antibody developability assessment pipeline measures expression yield, thermal stability, aggregation resistance, and chemical liabilities early in the discovery process, enabling rapid triage of candidates before costly late-stage attrition.

The single-domain architecture of VH domains supports high-yield expression in both microbial systems and mammalian cell systems such as CHO cells. HCAb VHs are also compatible with standard purification processes and can be formatted into multivalent or Fc-fusion constructs to extend half-life and add effector functions, while maintaining favorable thermal stability and low viscosity profiles. The unique genetic diversity encoded within the Harbour Mice® VH repertoire, which includes all human D and J gene segments, supports generation of panels recognizing diverse, functionally relevant epitopes across both mono- and multispecific programs.

When should a developer choose HCAbs over scFvs?

scFvs are the most prevalent compact binder format in clinical development today, used in approximately 36% of clinical-stage biotherapeutics compared to approximately 10% for VHH-based molecules. Despite this prevalence, scFvs frequently require extensive re-engineering to address stability and immunogenicity issues that emerge during development, creating costly delays and unpredictable clinical risk.

HCAbs from Harbour Mice® are the better starting point when the program involves multispecific construction, where chain mispairing is a manufacturing concern; when the target requires epitope access in sterically restricted regions, where the compact HCAb-derived single domains have structural advantages; or when the developer requires a fully human sequence from the outset to support a clean IND immunogenicity package. For programs where scFv precedent is strong and the target is well-validated with existing scFv tools, scFvs remain a viable option, but developers should account for the re-engineering burden in their timelines.

What clinical validation supports HCAb-based discovery at Nona?

Nona Biosciences’ fully human antibody discovery platform spans both H2L2 and HCAb formats from Harbour Mice®, with strategic collaborations including AstraZeneca and Pfizer that demonstrate the platform’s ability to generate clinically relevant candidates. Partnering with Nona offers strong global patent protection, clinical data backing, and proprietary platforms including Harbour Mice®, HBICE®, and NonaCarFx™.

No approved biotherapeutic has yet leveraged fully human VH domains, but multiple candidates have entered clinical evaluation, and the regulatory and immunogenicity rationale for fully human sequences over humanized alternatives is well-established. Nona’s platform is positioned to support the next wave of HCAb-derived clinical candidates through the Idea toward IND (I-to-I® ) pathway (Nona’s integrated end-to-end service pathway from ideation through IND filing), which covers target validation, immunization, screening, lead optimization, developability assessment, and IND-enabling studies under a single integrated framework.

How does Harbour Mice® compare to other transgenic platforms for HCAb discovery?

Harbour Mice® is the original and first transgenic platform developed to produce fully human HCAbs through natural in vivo immune selection using human VH gene segments and a constant region lacking CH1. With over 20 years of optimization, including careful selection of VH sequences that ensure highly developable binders, the HCAb Harbor Mice® provide a solid foundation for discovery. Alternative approaches either rely on camelid-derived VHH sequences that require humanization, or on scFv engineering that introduces linker-related instability risks.

The Harbour Mice® system is continually optimized to maintain strong immune responses and high antibody titers upon immunization, ensuring reliable generation of diverse, high-affinity VH domains across immunization campaigns. A key advantage of Nona’s approach is intentional V gene selection: Harbour Mice® are optimized around highly developable gene families such as HCAb V3, rather than attempting to use all human V genes indiscriminately. Platforms that use the full V gene repertoire without selection produce screening pools where a large proportion of candidates carry inherent biophysical liabilities — costing clients time and downstream attrition. By selecting for developability at the gene level, Harbour Mice® generates panels that are higher quality from the outset.

For developers seeking freedom to operate without the royalty structures associated with some competing transgenic platforms, Nona’s HCAb technology page provides detailed information on platform access and program structures. The combination of fully human sequence origin, natural affinity maturation, and broad epitope coverage makes Harbour Mice® the most clinically aligned source of compact VH binders currently available.

What is NonaCarFx™ and why does it matter for HCAb screening?

NonaCarFx™ is Nona’s proprietary CAR function-based screening platform and is currently the only platform of its kind available anywhere in the industry. It works exclusively with HCAb because HCAb relies on a single gene — unlike H2L2 formats that require complex heavy and light chain pairing, the single-domain architecture of HCAb allows immune cells to be processed directly into a cDNA library without losing the original gene pairing. This makes library-scale functional screening possible in a mammalian system.

NonaCarFx™ combines the speed of single-cell platforms like Beacon®, the throughput of phage display (screening 100,000–300,000 sequences per run, scalable to millions), and the functional readout that was previously only possible through hybridoma — without hybridoma’s slowness. For developers building in vivo CAR-T or cell therapy programs, this translates to identification of candidates selected on actual functional activity, not just binding. NonaCarFx™ is only possible because of the structural simplicity of HCAb, making it a direct downstream benefit of the manufacturing advantages described throughout this article.

To discuss how HCAb-based discovery could simplify your bispecific program’s manufacturing path, contact Nona’s antibody engineering team to explore a tailored Idea to IND® program design.

1. Hamers-Casterman C. et al., Naturally occurring antibodies devoid of light chains, Nature, 1993. Link

2. Janssens R. et al., Generation of heavy-chain-only antibodies in mice, PNAS, 2006. Link

3. Drabek D. et al., A transgenic heavy chain IgG mouse platform as a source of high affinity fully human single-domain antibodies for therapeutic applications, Methods in Molecular Biology, 2022. Link

4. Rossotti M.A. et al., Immunogenicity and humanization of single-domain antibodies, The FEBS Journal, 2022. Link

5. Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link

6. Aguilar Martínez I. et al., Next generation of multispecific antibody engineering, Antibody Therapeutics, 2023. Link

7. Raybould M.I.J. et al., Blueprint for antibody biologics developability, mAbs, 2023. Link

8. Sivalingam G.N. et al., Single B cell technologies for monoclonal antibody discovery, Trends in Immunology, 2021. Link

9. Klein C. et al., The present and future of bispecific antibodies for cancer therapy, Nature Reviews Drug Discovery, 2024. Link

10. Jovčevska I. & Muyldermans S., The therapeutic potential of nanobodies, BioDrugs, 2020. Link